Stevanato's 2024 revenue hits €1.1B, driven by biopharma growth! Discover how facility expansions & rising demand are transforming their market impact.

Proficio Capital Partners LLC acquired a new stake in Royalty Pharma plc (NASDAQ:RPRX – Free Report) in the fourth quarter, ...

Fate Therapeutics (NASDAQ:FATE – Free Report) had its target price trimmed by Wells Fargo & Company from $5.00 to $4.00 in a ...

Biopharma companies raised $2.98 billion through 59 transactions in February 2025, down from $5.91 billion across 93 deals in January. The year is off to a slower start compared to 2023, with the ...

Consumers are on board, with an estimated 26% of U.S. adults planning to take a weight loss drug in 2025, according to ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

Limited or Ligand Pharmaceuticals Incorporated is a better investment based on AAII's A+ Investor grades, which compare both ...

We recently compiled a list of the 10 Best Micro Cap Stocks to Buy Now. In this article, we are going to take a look at where ...

The term "game-changing" is overused for too many up-and-coming companies, but in this case, the description fits.

Maravai LifeSciences Holdings, Inc.’s MRVI share price has surged by 10.86%, which has investors questioning if this is right ...

Shares of Xeris Biopharma climbed after the company guided for higher revenue in 2025. The stock was up 17%, to $4.41, in Thursday trading, which is equivalent to the highest close since June 28, 2021 ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...